Catalyst Pharmaceuticals, Inc. CPRX
We take great care to ensure that the data presented and summarized in this overview for CATALYST PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CPRX
View all-
Black Rock Inc. New York, NY18.7MShares$421 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$190 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$131 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$70.6 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$67.9 Million0.02% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.96MShares$66.6 Million0.15% of portfolio
-
Goldman Sachs Group Inc New York, NY2.8MShares$63.1 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.71MShares$60.9 Million0.09% of portfolio
-
Geode Capital Management, LLC Boston, MA2.67MShares$60 Million0.0% of portfolio
-
First Trust Advisors LP Wheaton, IL2.23MShares$50.3 Million0.04% of portfolio
Latest Institutional Activity in CPRX
Top Purchases
Top Sells
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Insider Transactions at CPRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 06
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
180,096
-72.34%
|
$3,782,016
$21.67 P/Share
|
|
Mar 06
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
180,096
+41.97%
|
$360,192
$2.24 P/Share
|
|
Mar 05
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Open market or private sale
|
Direct |
44,904
-39.47%
|
$987,888
$22.09 P/Share
|
|
Mar 05
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,904
+28.3%
|
$89,808
$2.24 P/Share
|
|
Mar 03
2025
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
30,423
-100.0%
|
$669,306
$22.89 P/Share
|
|
Mar 03
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Open market or private sale
|
Direct |
62,975
-13.46%
|
$1,448,425
$23.08 P/Share
|
|
Mar 03
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
62,525
+11.26%
|
$125,050
$2.24 P/Share
|
|
Feb 14
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,353
-1.23%
|
-
|
|
Feb 14
2025
|
Brian Elsbernd Chief Compliance/Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,667
+4.82%
|
-
|
|
Feb 14
2025
|
Charles B O'Keeffe Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+0.54%
|
-
|
|
Feb 14
2025
|
Preethi Sundaram Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,965
-11.7%
|
-
|
|
Feb 14
2025
|
Preethi Sundaram Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,667
+24.64%
|
-
|
|
Feb 14
2025
|
Jeffrey Del Carmen Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,125
-9.32%
|
-
|
|
Feb 14
2025
|
Jeffrey Del Carmen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,667
+24.13%
|
-
|
|
Feb 14
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,435
-3.41%
|
-
|
|
Feb 14
2025
|
Gary Ingenito Chief Med. & Reg. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+12.3%
|
-
|
|
Feb 14
2025
|
Molly Harper Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+37.22%
|
-
|
|
Feb 14
2025
|
Steve Miller Chief Op. & Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,667
+1.42%
|
-
|
|
Feb 14
2025
|
Donald A Denkhaus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+0.8%
|
-
|
|
Feb 14
2025
|
David S Tierney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+1.11%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 2.09M shares |
|---|
| Payment of exercise price or tax liability | 50.4K shares |
|---|---|
| Open market or private sale | 1.66M shares |
| Bona fide gift | 50.1K shares |